Literature DB >> 18404682

DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.

Ken Kawamoto1, Hiroshi Hirata, Nobuyuki Kikuno, Yuichiro Tanaka, Masayuki Nakagawa, Rajvir Dahiya.   

Abstract

Secreted frizzled-related protein 2 (sFRP2) is a negative modulator of the Wingless-type (Wnt) signaling pathway, and shown to be inactivated in renal cell carcinoma (RCC). However, the molecular mechanism of silencing of sFRP2 is not fully understood. Our study was designed to elucidate the silencing mechanism of sFRP2 in RCC. Expression of sFRP2 was examined in 20 pairs of primary cancers by immunohistochemistry. Kidney cell lines (HK-2, Caki-1, Caki-2, A-498 and ACHN) were analyzed for sFRP2 expression using real-time RT-PCR and Western blotting. The methylation status at 46 CpG sites of the 2 CpG islands in the sFRP2 promoter was characterized by bisulfite DNA sequencing. Histone modifications were assessed by chromatin immunoprecipitation (ChIP) assay using antibodies against AcH3, AcH4, H3K4 and H3K9. sFRP2 was frequently repressed in primary cancers and in RCC cells. The majority of sFRP2 negative cells had a methylated promoter. Meanwhile, sFRP2 expression was repressed by a hypomethylated promoter in Caki-1 cells, and these cells had a repressive histone modification at the promoter. In Caki-1 cells, sFRP2 was reactivated by trichostatin A (TSA). Repressive histone modifications were also observed in RCC cells with hypermethylated promoters, but sFRP2 was reactivated only by 5-aza-2'-deoxycytidine (DAC) and not by TSA. However, the activation of the silenced sFRP2 gene could be achieved in all cells using a combination of DAC and TSA. This is the first report indicating that aberrant DNA methylation and histone modifications work together to silence the sFRP2 gene in RCC cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404682     DOI: 10.1002/ijc.23514

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer.

Authors:  Kazumori Kawakami; Soichiro Yamamura; Hiroshi Hirata; Koji Ueno; Sharanjot Saini; Shahana Majid; Yuichiro Tanaka; Ken Kawamoto; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

2.  Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.

Authors:  Wei Luo; Adam R Karpf; Kristin K Deeb; Josephia R Muindi; Carl D Morrison; Candace S Johnson; Donald L Trump
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

3.  Wnt antagonist gene polymorphisms and renal cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koichi Nakajima; Nobuyuki Kikuno; Soichiro Yamamura; Kazumori Kawakami; Yutaka Suehiro; Z Laura Tabatabai; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

4.  Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Authors:  Simon J Cooper; Christina A von Roemeling; Kylie H Kang; Laura A Marlow; Stefan K Grebe; Michael E Menefee; Han W Tun; Gerardo Colon-Otero; Edith A Perez; John A Copland
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

Review 5.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

Review 6.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

7.  Downregulation of sFRP-2 by epigenetic silencing activates the β-catenin/Wnt signaling pathway in esophageal basaloid squamous cell carcinoma.

Authors:  Tsuyoshi Saito; Hiroyuki Mitomi; Abdukadir Imamhasan; Takuo Hayashi; Keiko Mitani; Michiko Takahashi; Yoshiaki Kajiyama; Takashi Yao
Journal:  Virchows Arch       Date:  2014-01-26       Impact factor: 4.064

Review 8.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

9.  Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Authors:  Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood
Journal:  Int J Cancer       Date:  2012-09-28       Impact factor: 7.396

10.  Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma.

Authors:  Nithya Ramnath; Ernest Nadal; Chae Kyung Jeon; Juan Sandoval; Justin Colacino; Laura S Rozek; Paul J Christensen; Manel Esteller; David G Beer; So Hee Kim
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.